{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T20:12:38Z","timestamp":1770408758965,"version":"3.49.0"},"reference-count":7,"publisher":"IMR Press","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Hosp Med"],"published-print":{"date-parts":[[2021,5,2]]},"abstract":"<jats:sec>\n                    <jats:title>Aims\/Background<\/jats:title>\n                    <jats:p>Heart failure affects approximately 1 million people in the UK, adversely affecting quality of life, functional capacity and cognitive health. Iron deficiency complicates heart failure in approximately 50% of patients. Giving intravenous ferric carboxymaltose has been shown to improve quality of life in patients with heart failure (New York Heart Association class and Kansas City Cardiomyopathy Questionnaire).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A quality improvement project was designed to assess the feasibility, safety and cost implications of establishing an intravenous iron service in the authors' centre.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between July and December 2019 61 patients who were screened met the inclusion criteria and were administered intravenous ferric carboxymaltose. There were statistically significant improvements in ferritin levels (83.3 ug\/litre to 433 ug\/litre; P&lt;0.0001), transferrin saturation (18% to 30% P&lt;0.0001) and haemoglobin levels (126 g\/litre to 135 g\/litre; P&lt;0.01). No demonstrable changes in New York Heart Association class or quality of life scores were noted. The overall financial impact for the trust was income generation of \u00a314 665, a net income of \u00a3240 per patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intravenous iron replacement with ferric carboxymaltose is safe and cost effective, and should be considered in eligible iron-deficient patients with symptomatic heart failure. Integration with another day case intravenous service represented the most logistically simple and economically viable method of service delivery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.12968\/hmed.2021.0034","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T13:49:21Z","timestamp":1622036961000},"page":"1-5","source":"Crossref","is-referenced-by-count":0,"title":["Giving intravenous iron to patients with symptomatic heart failure is safe and cost effective"],"prefix":"10.31083","volume":"82","author":[{"given":"James","family":"Redfern","sequence":"first","affiliation":[{"name":"Department of Cardiology, Liverpool Heart and Chest Hospital, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Goode","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Liverpool Heart and Chest Hospital, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wing Yin","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Liverpool Heart and Chest Hospital, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Quarterman","sequence":"additional","affiliation":[{"name":"Department of Anaesthetics, Liverpool Heart and Chest Hospital, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Liverpool Heart and Chest Hospital, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.053"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-309573"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2017.04.007"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66621-4"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu385"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.07.015"}],"container-title":["British Journal of Hospital Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.magonlinelibrary.com\/doi\/pdf\/10.12968\/hmed.2021.0034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:02:10Z","timestamp":1770372130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/82\/5\/10.12968\/hmed.2021.0034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,2]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5,2]]}},"alternative-id":["10.12968\/hmed.2021.0034"],"URL":"https:\/\/doi.org\/10.12968\/hmed.2021.0034","relation":{},"ISSN":["1750-8460","1759-7390"],"issn-type":[{"value":"1750-8460","type":"print"},{"value":"1759-7390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,2]]}}}